This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Meloxicam 5mg/mL|
|Indication||Dogs. Alleviation of inflammation and pain in acute and chronic musculoskeletal disorders. Reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery. Cats. Reduction of pain after surgery. Management of febrile conditions in combination with appropriate antibiotics.|
|Contraindications||Administration to pregnant or lactating animals and animals less than 6 weeks of age. Administration to animals with gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or when there is evidence of individual hypersensitivity to the product. As for all NSAIDs, use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, careful clinical management may be required.|
|Actions||Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, antiexudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.|
|Precautions||Cats. Loxicom should be used as a single dose of 0.3 mg meloxicam/kg. Safety trials have demonstrated that meloxicam, when administered to cats subcutaneously at 0.3 mg/kg at 24 hour intervals for three consecutive days, resulted in no side effects in trial animals. Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.Pretreatment with other anti-inflammatory drugs prior to the use of Loxicom may result in additional or increased adverse effects; accordingly, a treatment free period with such drugs should be observed for at least 24 hours before commencement with Loxicom. The treatment free period, however, should take into account the pharmacokinetic properties of the drugs previously used.Parenteral administration of Loxicom is well tolerated without local adverse reactions. Typical adverse reactions of NSAIDs include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. These side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious. Hypovolaemia or hypotension should be corrected prior to use of the product. In case of overdosing, a symptomatic treatment should be initiated.First Aid If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.Disposal Dispose of empty contain by wrapping with paper and putting in garbage.|
|Dosage and Administration||Dogs. Musculoskeletal disorders. Single subcutaneous injection at a dosage of meloxicam 0.2 mg/kg bodyweight (i.e. 0.4 mL/10 kg). A suitable meloxicam suspension product may be used for continuation of treatment beginning after 24 hours. Reduction of postoperative pain. Single intravenous or subcutaneous injection at a dosage of meloxicam 0.2 mg/kg bodyweight (ie. 0.4 mL/10 kg) before surgery, for example at the time of induction of anaesthesia.Cats. Reduction of postoperative pain. Single subcutaneous injection at a dosage of meloxicam 0.3 mg/kg bodyweight (i.e. 0.06 mL/kg) directly prior to induction of anaesthesia. Management of febrile conditions. Single subcutaneous injection at a dosage of meloxicam 0.3 mg/kg bodyweight (i.e. 0.06 mL/kg).|
|Storage||Store below 25°C (air conditioning). Protect from light. Discard unused product 28 days after first broaching vial.|
|MSDS (external link)||Loxicom Injection MSDS|
|Label (external link)||Loxicom Injection Label|
|Manufacturer||Norbrook Laboratories Australia P/L|